Amodiaquine, its desethylated metabolite, or both, inhibit the metabolism of debrisoquine (CYP2D6) and losartan (CYP2C9) in vivo

By Wennerholm Agneta   Nordmark Anna   Pihlsgård Maria   Mahindi Margarita   Bertilsson Leif   Gustafsson Lars  

European Journal of Clinical Pharmacology, Vol. 62, Iss. 7, 2006-07 ,pp. : 539-546

Springer Publishing Company

Access to resources Recommend Favorite

Contribution of CYP2C9 to variability in vitamin K antagonist metabolism

By Daly Ann K   King Barry P  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 2, Iss. 1, 2006-02 ,pp. : 3-15

Informa Healthcare

Access to resources Recommend Favorite

Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation

By Miller Jackie   Trepanier Lauren  

European Journal of Clinical Pharmacology, Vol. 58, Iss. 1, 2002-04 ,pp. : 69-72

Springer Publishing Company

Access to resources Recommend Favorite

Comparison of Enzyme Kinetic Parameters Obtained In Vitro for Reactions Mediated by Human CYP2C Enzymes Including Major CYP2C9 Variants

By  

Current Drug Metabolism, Vol. 11, Iss. 2, 2010-02 ,pp. : 153-161

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitory effects of H-antihistamines on CYP2D6- and CYP2C9-mediated drug metabolic reactions in human liver microsomes

By He Nu   Zhang Wen-Qi   Shockley Dolores   Edeki Timi  

European Journal of Clinical Pharmacology, Vol. 57, Iss. 12, 2002-02 ,pp. : 847-851

Springer Publishing Company

Access to resources Recommend Favorite